There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

Wegovy maker Novo Nordisk has ended its legal dispute with the Hims & Hers Health platform, according to a media report.

The two companies are likely to partner and sell the blockbuster obesity drug Wegovy together on the Hims & Hers Health platform, Bloomberg News reported.

Market analysts have expressed surprise on the move, as both Novo and Hims have been previously engaged in legal battle over Wegovy.

“There is no other way to describe the Hims news as both a surprise and an unabashed positive for Hims' stock,” Leerink Partners analyst Michael Cherny was quoted as saying in a note to clients.

A Novo spokesperson said in an emailed statement that the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".

The Dispute Between Novo and Hims

In February, Novo sued Hims for launching a similar version of its new Wegovy weight-loss pill for $49.

The Danish drugmaker accused Hims of patent infringement on Semaglutide -- the active ingredient behind its best-selling medications Ozempic and Wegovy.

Semaglutide is popularly known for weight loss , but is also effective for diabetes and is used primarily for that.

The US Food and Drug Administration (FDA) had also threatened action against Hims.

Last year, Novo had to end a short-lived agreement to sell Wegovy over Him's marketing tactics and continued sales of copycat versions of Wegovy.

Recently, the FDA has signaled plans to crack down on the proliferation of copycat, or compounded, weight-loss drugs.

Wegovy And Ozempic To Cost Less In 2027

Currently, Wegovy injections and pills cost $1,349.02 a month, whereas Ozempic and Rybelus cost $1,027.51, Novo told PEOPLE.

Individuals with commercial insurance pay $25 a month, whereas those using cash pay between $149 to $499. Patients on Medicare will pay $274 per month.

Late in February, Novo Nordisk announced it would slash the price for all doses:

• The list price of Wegovy injections and the new Wegovy pill will be cut in half
• Ozempic injections will be cut by 35 percent
• The semaglutide tablet Rybelsus will now cost $675 a month

"There are more than 100 million people living with obesity and over 35 million with type 2 diabetes and, and for some, list price has been a real barrier to access and affordability," Jamey Millar, Executive Vice President, US Operations of Novo Nordisk Inc., was quoted as saying to PEOPLE.

Indian Drugmakers Rush For Generic Weight Loss Drugs

Meanwhile, amid the patent expiration of semaglutide, several pharma companies in India are planning big launches of Wegovy's generic versions.

Several leading drugmakers have already secured regulatory approval or recommendations to produce and market generic versions of the weight loss drugs in the country.

Hyderabad-based Dr. Reddy's already applied for a trademark with the brand name Obeda and a logo.

Other companies like Sun Pharma, Zydus Lifesciences, and Nacto Pharma are also entering the rat race of launching multiple generic versions to make the treatment more affordable for patients with obesity and weight-related health risks.

Sun Pharma also announced the plans for "day-one" launches of generic prefilled pens.

The US Food and Drug Administration (FDA)’s Vinay Prasad has once again — for the second time in less than a year — stepped down from his post as director of the agency’s Center for Biologics Evaluation and Research, amid controversies over the review of vaccines and specialty drugs for rare diseases.

Announcing the news to FDA staff in an email late Friday, FDA Commissioner Marty Makary said Prasad would depart at the end of April. Makary added that Prasad would return to his academic position at the University of California, San Francisco (UCSF).

Taking to social media platform X, Makary said that under Prasad’s leadership, his center recorded a record number of approvals in December.

“A year ago, Dr. Prasad came to the FDA to implement four major long-lasting reforms: a 2-to-1 pivotal trial requirement, national priority reviews, a risk-stratified COVID vaccine framework, and the new plausible mechanism framework for ultra-rare diseases, which we launched last week,” Makary said.

The FDA commissioner noted that Prasad “got a tremendous amount accomplished within his one-year sabbatical from UCSF and will be returning to his academic home later next month,” and thanked him “for his service and personal sacrifice in taking time away from his family.”

The FDA is expected to announce Prasad’s successor before his departure.

Who Is Vinay Prasad?

Vinay Prasad is an Indian-origin American hematologist-oncologist and author. He was first appointed as the FDA’s vaccines chief in May 2025.

Prasad, known as a longtime critic of the FDA’s standards for drug reviews, drew controversy for raising the bar for new drug approvals. The move did not sit well with pharmaceutical companies and reportedly dashed the hopes of some patients with rare diseases.

In July, he was removed from his position following disputes with biotechnology executives, patient organisations, and conservative allies of US President Donald Trump. He was later reinstated after Makary and US Health Secretary Robert F. Kennedy Jr. pushed for reconsideration.

What Is The Controversy?

While Prasad, along with Makary, announced several measures to make FDA drug reviews faster and easier for companies, he also imposed new warnings and study requirements for some biotech drugs and vaccines.

This was particularly evident in the case of COVID-19 vaccines, which have been a target of criticism from Kennedy, who was a longtime anti-vaccine activist before joining the Trump administration.

The latest controversy involves the FDA’s interactions with Dutch biopharma company uniQure, which developed an experimental gene therapy for Huntington’s disease that is injected directly into the brain during a surgical procedure.

Huntington’s is a deadly neurological condition affecting about 40,000 Americans, and currently has no cure.

UniQure faced a setback after Prasad’s centre said its earlier studies were insufficient to support a biologics licence application.

During an earnings call earlier this week, the company said the FDA was demanding a new trial involving sham surgery for some patients.

Executives said the request for a sham-controlled trial contradicted earlier FDA guidance. They also questioned whether such an approach would be ethical for patients with Huntington’s disease, which is progressive and ultimately fatal, typically in middle age.

Earlier, Prasad also refused to allow the FDA to review a highly anticipated flu vaccine from Moderna made using mRNA technology.

The rejection of the application -- highly unusual for the FDA -- prompted Moderna to go public with Prasad’s decision and vow to formally challenge it.

A week after the rejection became public, the FDA reversed course and said it would accept the vaccine for review, pending an additional study from the company.

Prasad’s handling of rare-disease therapy applications also drew criticism after the FDA asked Sarepta Therapeutics, a drugmaker developing treatments for Duchenne muscular dystrophy, to pause shipments following reports of patient deaths.

The company initially resisted, wanting to continue distributing treatments for patients who could still walk, but later agreed. The agency, however, reversed the pause just days later.

Duchenne muscular dystrophy affects a small number of boys and young men who typically lose their ability to walk before puberty and often die by around age 30.

Union Health Minister JP Nadda has announced that cervical cancer screenings using Visual Inspection with Acetic Acid (VIA) will now be available at Ayushman Arogya Mandirs and other health facilities for women between 30 and 65 years of age.

"Screening for cervical cancer is now available at 1,81,000 Ayushman Arogya Mandirs, also known as Health and Wellness Centers, across the country as a part of population based screening for early detection and treatment," said Nadda, while addressing a press briefing at the World Health Organization virtually.

Using VIA, a low-cost, point-of-care method, trained health workers will screen women for cervical cancer. Those who test positive will then be referred to higher centers for diagnostic confirmation and further evaluation.

Nadda also shared that the cervical cancer screening in the country has been expanded as part of comprehensive primary healthcare under the National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD).

"Over 86 million women have already been screened for cervical cancer under the program, reflecting India’s sustained commitment to early detection and prevention," Nadda informed.

Despite being highly preventable as well as treatable, cervical cancer is a public health concern in India.

The country loses one women every eight minutes to cervical cancer.

As per the World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, about 42,000 new cases of cervical cancer is reported annually in India. This underscores the need for preventive measures such as vaccination and early screening.

The WHO Global Strategy to eliminate cervical cancer includes the 90-70-90 targets by 2030 -- vaccinating 90 per cent of girls against HPV, screening 70 percent of women, and ensuring treatment for 90 percent of those diagnosed with cervical disease.

In line with the global strategy to fight cervical cancer, Prime Minister Narendra Modi recently also launched a free HPV vaccination drive that will target health and well being of adolescent girls in the country.

What Is Cervical Cancer?

Cervical cancer develops in a women's cervix (uterus opening) due to abnormal cell growth, primarily caused by persistent HPV infection, a common infection that's passed through sexual contact.

When exposed to HPV, the body's immune system typically prevents the virus from causing damage however, in a small percentage of people, the virus can survive for years and pave the way for some cervical cells to become cancerous.

Treatment involves surgery, radiation, and chemotherapy, with early detection significantly improving outcomes, though it remains a major cancer in low-income countries Cervical cancer can also be prevented through vaccination and regular screening (Pap/HPV tests).

Symptoms Of Cervical Cancer

Cervical cancer has no symptoms in the early days and therefore, is hard to detect until it has spread. However, the early-stage symptoms include:

• Vaginal bleeding after sex
• Vaginal bleeding post-menopause
• Vaginal bleeding between periods or unusually heavy/long periods
• Watery vaginal discharge with a strong odour or containing blood
• Pelvic pain or pain during intercourse
• Advanced Cervical Cancer Symptoms (when cancer has spread beyond the cervix)
• Painful or difficult bowel movements or rectal bleeding
• Painful or difficult urination or blood in the urine
• Persistent dull backache
• Swelling of the legs
• Pain in the pelvis or lower abdomen

How Can Cervical Cancer Be Prevented?

Cervical cancer is largely preventable and, when detected early, it is highly treatable. The WHO recommends HPV vaccination for girls aged 9 to 14, before they become sexually active, along with regular cervical screening from age 30, or 25 for women living with HIV.

Despite this, unequal access to vaccination, screening and treatment continues to drive higher rates of illness and deaths in regions such as sub-Saharan Africa, Central America and Southeast Asia.